ALKEM
Inspiring Healthier Lives

ALKEM LABORATORIES LTD.
Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

12th November, 2026

To,

The Corporate Relationship Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. ***Scrip Code: 539523***	**National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. ***Scrip Symbol: ALKEM***

Sub: Outcome of the Board Meeting held on 12th November, 2026

Dear Sir(s)/ Madam,

This is in reference to our earlier intimation dated 04th November, 2026, pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), regarding holding of Board Meeting on 12th November, 2026 to *inter alia* approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026.

The Board of Directors at its meeting held today, i.e. 12th November, 2026 has approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed herewith.

The meeting of the Board of Directors of the Company commenced at 11.30 a.m. and concluded at 01.40 p.m.

The above information is also available on the website of the Company at www.alkemlabs.com

Kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

Deloitte
Haskins & Sells LLP

Chartered Accountants
One International Center,
Tower 3, 31st Floor,
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai - 400 013
Maharashtra, India

Tel: +91 22 6185 6000
Fax: +91 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ALKEM LABORATORIES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Alkem Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net loss after tax and total comprehensive income of its associate for the quarter and six months ended September 30, 2026 ("the Statement") which includes the branch of the Group located at Nepal, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure 1 to this report.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Deloitte
Haskins & Sells LLP

6. We did not review the interim financial information / financial results of five subsidiaries included in the consolidated unaudited financial results, whose interim financial information / financial results reflect total assets of Rs.15,803.8 million as at September 30,2026 and, total revenues of Rs.6,013.9 million and Rs.8,959.0 million for the quarter and six months ended September 30, 2026 respectively, total net profit after tax of Rs.401.6 million and Rs.449.4 million for the quarter and six months ended September 30,2026 respectively and total comprehensive income of Rs. 348.3 million and Rs.414.6 million for the quarter and six months ended September 30,2026 respectively and net cash inflow of Rs.30.8 million for the six months ended September 30,2026, as considered in the Statement. These interim financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim financial information of twenty eight subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs.11,605.5 million as at September 30,2026 and, total revenue of Rs.1,661.7 million and Rs.3,923.7 million for the quarter and six months ended September 30, 2026 respectively, total net loss after tax of Rs.284.2 million and Rs.384.9 million for the quarter and six months ended September 30,2026 respectively and total comprehensive income of (Rs. 274.7 million) and (Rs.357.5 million) for the quarter and six months ended September 30,2026 respectively and net cash inflow of Rs.650.9 million for the six months ended September 30,2026, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs.6.1 million and Rs.11.2 million for the quarter and six months ended September 30,2026 respectively and total comprehensive income of (Rs.6.1 million) and (Rs.11.2 million) for the quarter and six months ended September 30,2026 respectively, as considered in the Statement, in respect of one associate, based on its interim financial information which has not been reviewed by its auditor. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information / results certified by the Management.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Rupen K. Bhatt
(Partner)
(Membership No. 046930)
(UDIN: 26046930DWPN1Y9482)

Place: Mumbai
Date: November 12, 2026

Deloitte
Haskins & Sells LLP

ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT
(Referred to in paragraph 4 under Independent Auditor's Review Report of even date)

S.N.	Name of the component	Relationship
1	Alkem Laboratories Limited	Parent
2	S&B Holdings S.a.r.l	Wholly Owned Subsidiary
3	The Pharma Network LLC, USA (TPN)	Wholly Owned Subsidiary of S&B Holdings S.a.r.l.
4	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
5	S & B Pharma LLC	Wholly Owned Subsidiary of TPN
6	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7	Pharmacor SPA, Chile	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
8	Enzene Biosciences ltd, India	Subsidiary
9	Ascend Laboratories (PTY) Ltd, South Africa	Wholly Owned Subsidiary
10	Cachet Pharmaceuticals Private Limited, India	Subsidiary
11	Indchemie Health Specialties Private Limited, India	Subsidiary
12	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
13	Ascend GmbH, Germany	Wholly Owned Subsidiary
14	Ascend Laboratories SDN BHD., Malaysia	Wholly Owned Subsidiary
15	Ascend Laboratories SpA Chile (Ascend Chile)	Wholly Owned Subsidiary
16	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
17	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
18	Alkem Laboratories Korea Inc, Korea	Wholly Owned Subsidiary
19	Pharmacor Ltd, Kenya	Wholly Owned Subsidiary
20	The Pharma Network LLP, Kazakhstan	Wholly Owned Subsidiary
21	Ascend Laboratories (UK) Ltd, UK	Wholly Owned Subsidiary
22	Ascend Laboratories Ltd, Canada	Wholly Owned Subsidiary
23	Alkem Foundation, India	Wholly Owned Subsidiary
24	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
25	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
26	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
27	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India
28	Alkem Medtech Private Limited, India	Wholly Owned Subsidiary
29	Alkem Medtech Ortho Private Limited (w.e.f 16 April 2025)	Wholly Owned Subsidiary of Alkem Medtech Private Limited
30	Alixer Nexgen Therapeutics Limited	Wholly Owned Subsidiary
31	Alkem Wellness Limited	Wholly Owned Subsidiary
32	Adroit Biomed Limited, India (w.e.f 23 April 2025)	Wholly Owned Subsidiary
33	Alkem Pharmaceuticals Scientific Office FZ LLC, Dubai (incorporated on 4 February 2026)	Wholly Owned Subsidiary
34	Alkem Pharma Trading FZCO, Dubai (incorporated on 27 March 2026)	Wholly Owned Subsidiary
35	Haystack Analytics Private Limited	Associate
36	Occlutech Holding AG (Switzerland)(w.e.f 16 July 2026)	Subsidiary of Alkem MedTech Private Limited
37	Occlutech AG (Switzerland)	Wholly Owned Subsidiary of Occlutech Holding AG (Switzerland)

38	Occlutech Gmbh (Germany)	Wholly Owned Subsidiary of Occlutech AG (Switzerland)
39	Occlutech International AB (Sweden)	Wholly Owned Subsidiary of Occlutech AG (Switzerland)
40	Occlutech Tibbi Urunler Sanayi ve Ticaret Ltd Sirketi (Turkey)	Wholly Owned Subsidiary of Occlutech AG (Switzerland)
41	Occlutech France Sarl (France)	Wholly Owned Subsidiary of Occlutech AG (Switzerland)
42	Occlutech Italia s.r.l (Italy)	Wholly Owned Subsidiary of Occlutech AG (Switzerland)
43	Occlutech Uk Ltd (UK)	Wholly Owned Subsidiary of Occlutech AG (Switzerland)
44	Occlutech US LLC (US)	Wholly Owned Subsidiary of Occlutech AG (Switzerland)
45	OCCLUTECH POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ (Poland)	Wholly Owned Subsidiary of Occlutech AG (Switzerland)
46	Occlutech Canada Inc. (Canada)	Wholly Owned Subsidiary of Occlutech AG (Switzerland)

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201
Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.
Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190
Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Consolidated Financial Results for the Quarter and Six months ended 30 September 2026

(₹ in Million except per share data)

	Particulars	Quarter ended			Six months ended		Year ended
		30.09.2026 Unaudited	30.06.2026 Unaudited	30.09.2025 Unaudited	30.09.2026 Unaudited	30.09.2025 Unaudited	31.03.2026 Audited
1	**Income**						
	(a) Revenue from Operations	**45,519.9**	37,401.5	40,009.9	**82,921.4**	73,721.3	147,122.7
	(b) Other Income	**1,342.1**	1,527.5	1,036.9	**2,869.6**	2,401.8	5,833.5
	Total Income	**46,862.0**	38,929.0	41,046.8	**85,791.0**	76,123.1	152,956.2
2	**Expenses**						
	(a) Cost of materials consumed	**10,830.3**	9,100.2	9,055.7	**19,930.5**	17,326.8	35,653.9
	(b) Purchases of stock-in-trade	**4,688.3**	3,659.9	4,715.7	**8,348.2**	8,687.7	16,945.0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	**(571.1)**	(747.4)	238.9	**(1,318.5)**	(292.6)	(1,671.2)
	(d) Employee benefits expense	**8,965.2**	8,089.0	7,102.5	**17,054.2**	14,035.0	28,371.1
	(e) Finance costs	**576.7**	466.2	350.2	**1,042.9**	648.0	1,607.8
	(f) Depreciation and amortisation expense	**1,370.8**	1,001.9	936.1	**2,372.7**	1,812.9	3,820.6
	(g) Other expenses	**11,355.3**	9,639.3	9,689.4	**20,994.6**	17,366.2	37,771.8
	Total Expenses	**37,215.5**	31,209.1	32,088.5	**68,424.6**	59,584.0	122,499.0
3	**Profit before exceptional items and tax (1) - (2)**	**9,646.5**	7,719.9	8,958.3	**17,366.4**	16,539.1	30,457.2
4	**Exceptional items (refer note 3)**	**350.0**	-	-	**350.0**	129.3	(1,748.3)
5	**Profit before tax (3) + (4)**	**9,996.5**	7,719.9	8,958.3	**17,716.4**	16,668.4	28,708.9
6	**Tax expense / (credit) (Refer note 4)**						
	(a) Current tax	**4,053.4**	2,320.6	1,799.5	**6,374.0**	3,210.6	6,196.6
	(b) Deferred tax	**(734.3)**	184.4	(637.2)	**(549.9)**	(1,021.4)	(1,019.0)
	Total Tax Expense (a + b)	**3,319.1**	2,505.0	1,162.3	**5,824.1**	2,189.2	5,177.6
7	**Share in loss after tax of associate**	**(6.1)**	(5.1)	(4.9)	**(11.2)**	(9.0)	(19.7)
8	**Profit for the period (5) - (6) + (7)**	**6,671.3**	5,209.8	7,791.1	**11,881.1**	14,470.2	23,511.6
9	**Other Comprehensive Income/(Loss) (net of tax)**						
	(a) (i) Items that will not be reclassified to profit or loss	**(29.0)**	(25.4)	(44.9)	**(54.4)**	(92.5)	120.9
	(ii) Income tax relating to items that will not be reclassified to profit or loss	**5.4**	8.4	26.6	**13.8**	29.5	(38.1)
	(b) (i) Items that will be reclassified to profit or loss	**(92.3)**	45.8	447.0	**(46.5)**	512.5	1,755.1
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income/(Loss) (net of tax)	**(115.9)**	28.8	428.7	**(87.1)**	449.5	1,837.9
10	**Total Comprehensive Income for the period (8) + (9)**	**6,555.4**	5,238.6	8,219.8	**11,794.0**	14,919.7	25,349.5
11	**Profit attributable to**						
	a) Owners of the Company	**6,753.4**	5,199.6	7,650.6	**11,953.0**	14,293.2	23,018.0
	b) Non-Controlling Interest	**(82.1)**	10.2	140.5	**(71.9)**	177.0	493.6
12	**Other Comprehensive Income/(Loss) attributable to**	-					
	a) Owners of the Company	**(77.0)**	29.0	432.4	**(48.0)**	455.5	1,823.8
	b) Non-Controlling Interest	**(38.9)**	(0.2)	(3.7)	**(39.1)**	(6.0)	14.1
13	**Total Comprehensive Income attributable to**	-					
	a) Owners of the Company	**6,676.4**	5,228.5	8,083.0	**11,905.0**	14,748.7	24,841.8
	b) Non-Controlling Interest	**(121.0)**	10.1	136.8	**(111.0)**	171.0	507.7
14	**Paid-up Equity Share Capital** (Face Value ₹ 2 each fully paid up)	**239.1**	239.1	239.1	**239.1**	239.1	239.1
15	**Other Equity**						137,961.9
16	**Earnings Per Share (not annualised for the periods) (face value of ₹ 2/- each)**						
	(a) Basic (₹)	**56.48**	43.49	63.99	**99.97**	119.55	192.51
	(b) Diluted (₹)	**56.48**	43.49	63.99	**99.97**	119.55	192.51

Statement of Consolidated Assets and Liabilities as at 30 September 2026

(₹ in Million)

Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
I. ASSETS		
1 Non-current assets		
(a) Property, plant and equipment	**27,074.5**	26,949.7
(b) Right of use assets	**4,466.7**	3,956.6
(c) Capital work-in-progress	**1,607.9**	1,379.1
(d) Goodwill	**12,210.2**	5,236.4
(e) Other intangible assets	**13,607.6**	2,567.6
(f) Intangible assets under development	**1,421.9**	1,438.8
(g) Financial Assets		
(i) Investment in associate	**336.9**	348.1
(ii) Other investments	**11,834.4**	10,966.9
(iii) Other financial assets	**7,249.8**	12,157.4
(h) Deferred tax assets (net)	**17,471.8**	18,193.5
(i) Current tax assets (net)	**836.9**	799.6
(j) Other non-current assets	**2,656.4**	2,630.8
Total Non-current assets	**100,775.0**	86,624.5
2 Current assets		
(a) Inventories	**35,252.7**	33,332.2
(b) Financial Assets		
(i) Investments	**8,559.7**	7,373.1
(ii) Trade receivables	**33,700.5**	29,791.1
(iii) Cash and cash equivalents	**4,084.3**	2,479.1
(iv) Bank balances other than (iii) above	**2,091.0**	14,849.9
(v) Loans	**90.9**	66.3
(vi) Other financial assets	**35,789.2**	25,225.2
(c) Other current assets	**10,253.1**	8,988.3
Total Current assets	**129,821.4**	122,105.2
TOTAL ASSETS	**230,596.4**	208,729.7
II. EQUITY AND LIABILITIES		
1 Equity		
(a) Equity share capital	**239.1**	239.1
(b) Other Equity	**148,413.0**	137,961.9
Equity attributable to owners of the Company	**148,652.1**	138,201.0
(c) Non-controlling interest	**8,237.9**	5,288.3
Total Equity	**156,890.0**	143,489.3
2 Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	**10,334.6**	4,924.5
(ii) Lease liabilities	**3,889.7**	3,767.8
(iii) Other financial liabilities	**5,779.0**	4,077.0
(b) Provisions	**4,416.4**	4,312.1
(c) Deferred tax liabilities (net)	**2,033.9**	151.2
(d) Other non-current liabilities	**161.9**	180.8
Total Non-current liabilities	**26,615.5**	17,413.4
3 Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	**8,296.0**	11,310.5
(ii) Lease liabilities	**576.4**	468.8
(iii) Trade payables		
Dues of micro and small enterprises	**1,313.7**	1,971.4
Dues of Creditors other than micro and small enterprises	**19,721.3**	20,470.4
(iv) Other financial liabilities	**9,478.1**	7,742.3
(b) Other current liabilities	**3,498.9**	3,191.7
(c) Provisions	**2,195.9**	2,006.5
(d) Current tax Liabilities (Net)	**2,010.6**	665.4
Total Current liabilities	**47,090.9**	47,827.0
Total Liabilities	**73,706.4**	65,240.4
TOTAL EQUITY AND LIABILITIES	**230,596.4**	208,729.7

Statement of Consolidated Cash flow for the six months ended 30 September 2026

(₹ in million)

	Particulars	For the six months ended 30 September 2026 (Unaudited)	For the six months ended 30 September 2025 (Unaudited)
A	**Cash Flow from Operating Activities:**		
	Profit before tax and after exceptional items	**17,716.4**	16,668.4
	Adjustments for:		
	Depreciation and amortisation expense	**2,372.7**	1,812.9
	Profit on sale of investments (net)	**(236.7)**	(281.6)
	Unrealised loss/ (gain) on fair valuation of investments (net)	**(31.0)**	284.5
	(Profit)/Loss on sale / write off of property plant and equipment (net)	**1.1**	(143.9)
	Employee stock compensation expenses	**(7.2)**	33.5
	Unrealised foreign currency (gain)/loss on revaluation (net)	**86.3**	(301.5)
	Dividend income	**(0.7)**	(0.5)
	Interest income	**(2,160.5)**	(1,919.0)
	Interest expenses	**1,042.9**	648.0
	Provision for doubtful advances	**-**	(4.8)
	Expected credit loss on receivables	**98.2**	354.0
	Subtotal of adjustments	**1,165.1**	481.6
	Operating profit before working capital changes	**18,881.5**	17,150.0
	Adjustments for changes in working capital:		
	Increase in trade receivables	**(3,339.1)**	(5,372.0)
	Increase in loans, other financial assets and other assets	**(1,080.6)**	(1,137.1)
	Increase in inventories	**(725.3)**	(111.1)
	Increase in trade payable, other financial liabilities and other liabilities	**367.9**	140.5
	Increase in provisions	**18.0**	52.3
	Subtotal of adjustments	**(4,759.1)**	(6,427.4)
	Cash generated from operations	**14,122.4**	10,722.6
	Less: Income taxes paid (net of refund)	**(3,676.6)**	(2,356.9)
	Net cash generated from operating activities	**10,445.8**	8,365.7
B	**Cash Flow from Investing Activities:**		
	Purchases of property, plant and equipment (including capital work in progress, other intangible assets and intangible assets under development net off capital advances and capital creditors)	**(3,208.9)**	(3,964.2)
	Proceeds from disposal of property, plant and equipment	**135.9**	1,082.5
	Investments made in fixed deposits	**(8,122.6)**	(18,313.3)
	Redemption of fixed deposits	**15,610.0**	12,546.6
	Other investments made	**(28,018.0)**	(17,608.9)
	Redemption of other investments	**26,133.2**	10,720.5
	Recovery from impaired investment	**51.0**	
	Purchase consideration for acquisition of business (net of cash and cash equivalents acquired)	**(8,080.4)**	(1,714.9)
	Dividend received	**0.7**	0.5
	Interest received	**1,716.0**	1,567.6
	Net cash used in investing activities	**(3,783.1)**	(15,683.6)
C	**Cash Flow from Financing Activities:**		
	Proceeds from non-current borrowings	**9,472.2**	1,660.9
	Repayment of non-current borrowings	**(9,536.2)**	(547.5)
	Proceeds/ (repayment) of current borrowings (net)	**(2,828.6)**	5,209.2
	Dividend paid	**(1,248.2)**	(995.7)
	Proceeds from minority interest	**1,024.0**	-
	Principal repayment of lease liabilities	**(444.9)**	(246.3)
	Interest paid	**(877.5)**	(447.5)
	Net cash (used in) / generated from financing activities	**(4,439.2)**	4,633.1
D	**Net decrease in Cash and Cash Equivalents (A+B+C)**	**2,223.5**	(2,684.8)
E	**Cash & Cash Equivalents as at the beginning of the period (net of loans repayable on demand from banks)**	**(3,421.4)**	(1,200.9)
	Add: Effect of exchange difference on foreign currency cash and cash equivalents	**28.2**	4.1
F	**Cash & Cash Equivalents as at the end of the period (net of loans repayable on demand from banks) (D+E)**	**(1,169.7)**	(3,881.6)

Notes:

1 **Components of cash and cash equivalents for the purpose of Cash flow as per IND AS 7:**

Cash and cash equivalents	**4,084.3**	2,261.0
Loans repayable on demand from banks	**(5,254.0)**	(6,142.6)
Total cash and cash equivalents (net of loans repayable on demand from banks)	**(1,169.7)**	(3,881.6)

2 The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - "Statement of Cash Flows".

Notes to the Consolidated Financial results:

1 The above consolidated financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'.

2 The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 11 November 2026 and subsequently approved by the Board of Directors at its meeting held on 12 November 2026. The auditors have issued an unmodified review report on the financial results for the quarter and six months ended 30 September 2026.

3 a) Exceptional item for the quarter and six months ended 30 September 2026 represents recovery of ₹ 350 million against investment made, which was impaired during the quarter and year ended 31 March 2026.

b) Exceptional item amounting to ₹142.9 million for the six months ended 30 September 2025 is on account of gain on sale of Indore facility which was impaired earlier.

c) Exceptional items amounting to ₹1,748.3 million for the year ended 31 March 2026 mainly includes
- Impact of labour code of ₹ 1,130.6 million towards gratuity and leave encashment for past service cost;
- Impairment of real estate investment made of ₹747 million;
- Gain on sale of Indore facility of ₹142.9 million.

4 During the quarter and year ended 31 March 2026, pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Parent Company and one of its Indian subsidiary; had decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax had been recognised at the substantially enacted rate for the year ended 31 March 2026. Subsequently in the current period, the tax expense has been recognized based on the enacted tax rates applicable under the new regime.

5 During the quarter ended 30 September 2026, Alkem Medtech Private Limited (AMPL), a wholly owned subsidiary of the Parent Company, completed the acquisition of a 55% equity stake in Occlutech Holding AG ("Occlutech") pursuant to the Share Purchase Agreement (SPA). The acquisition of controlling interest was completed on 16 July 2026 for a fair value consideration of EUR 97.8 million (approx ₹ 10,797.6 million) (comprising cash consideration of ₹ 8,778.3 million and deferred consideration of ₹ 2,019.3 million), subject to adjustments in accordance with the terms of the SPA.

Accordingly, Occlutech became a subsidiary of the Group with effect from the acquisition date, and its financial results have been consolidated from 16 July 2026. Consequently, the results for the current period are not comparable with those of the corresponding previous periods.

The acquisition has been accounted for in accordance with Ind AS 103, Business Combinations. Based on the provisional Purchase Price Allocation (PPA), identifiable assets and liabilities acquired amounted to ₹ 16,047.8 million and ₹ 9,208.6 million (including deferred tax liability of ₹ 1,724.0 million) respectively. The acquisition resulted in recognition of goodwill of ₹ 7,036.0 million. The PPA will be finalised within the measurement period permitted under Ind AS 103, and any resulting adjustments will be recognized retrospectively from the acquisition date.

6 Segment information for the consolidated results for the quarter and six months ended September 30, 2026

(₹ in Million)

Particulars	Quarter ended			Six months ended		Year ended
	30.09.2026 Unaudited	30.06.2026 Unaudited	30.09.2025 Unaudited	**30.09.2026 Unaudited**	30.09.2025 Unaudited	31.03.2026 Audited
Segment revenues						
Pharmaceuticals	**43,479.2**	36,533.2	38,899.9	**80,012.4**	71,680.6	143,908.6
Biotech	**1,297.9**	1,198.6	1,582.2	**2,496.5**	2,940.1	4,922.6
MedTech	**1,331.4**	76.5	27.0	**1,407.9**	50.6	137.8
Total	**46,108.5**	37,808.3	40,509.1	**83,916.8**	74,671.3	148,969.0
Less: Inter-segment revenues	**(588.6)**	(406.8)	(499.2)	**(995.4)**	(950.0)	(1,846.3)
Total revenue from operations	**45,519.9**	37,401.5	40,009.9	**82,921.4**	73,721.3	147,122.7
Segment results						
Pharmaceuticals	**10,518.8**	7,693.9	8,331.2	**18,212.7**	14,872.7	27,921.0
Biotech	**(1,141.4)**	(912.8)	3.5	**(2,054.2)**	37.4	(1,063.5)
MedTech	**(496.3)**	(122.5)	(63.1)	**(618.8)**	(124.8)	(626.0)
Profit before interest, unallocable income, exceptional items and tax	**8,881.1**	6,658.6	8,271.6	**15,539.7**	14,785.3	26,231.5
Less: Finance costs	**576.7**	466.2	350.2	**1,042.9**	648.0	1,607.8
Add: Other income	**1,342.1**	1,527.5	1,036.9	**2,869.6**	2,401.8	5,833.5
Total profit before tax and exceptional items	**9,646.5**	7,719.9	8,958.3	**17,366.4**	16,539.1	30,457.2
Segment assets						
Pharmaceuticals	**101,889.5**	97,368.9	94,266.1	**101,889.5**	94,266.1	96,923.5
Biotech	**16,884.0**	17,023.9	16,151.1	**16,884.0**	16,151.1	17,110.0
MedTech	**24,863.4**	3,912.4	3,060.2	**24,863.4**	3,060.2	3,755.2
Unallocated assets	**86,959.5**	98,315.7	89,397.1	**86,959.5**	89,397.1	90,941.0
Total	**230,596.4**	216,620.9	202,874.5	**230,596.4**	202,874.5	208,729.7
Segment liabilities						
Pharmaceuticals	**41,535.5**	39,099.3	36,759.4	**41,535.5**	36,759.4	41,467.4
Biotech	**6,164.9**	5,979.9	6,085.6	**6,164.9**	6,085.6	5,992.3
MedTech	**3,330.7**	568.5	549.0	**3,330.7**	549.0	729.0
Unallocated liabilities	**22,675.3**	22,479.3	21,371.2	**22,675.3**	21,371.2	17,051.7
Total	**73,706.4**	68,127.0	64,765.2	**73,706.4**	64,765.2	65,240.4


Notes

Pursuant to the acquisition of a controlling interest in Occlutech Holding AG in July 2026, the Group reassessed its reportable operating segments following changes in the information being reviewed by the Chief Operating Decision Maker (CODM). Based on the revised internal reporting, the Group has identified Pharmaceuticals, Biotech and MedTech as its reportable operating segments.

Following the change in the composition of the Group's reportable operating segments, comparative segment information for the prior periods presented has been prepared on the basis of the current reportable segment structure to facilitate comparability. Accordingly, segment information has been presented in accordance with the requirements of Ind AS 108.

The Group's treasury operations are managed centrally. Accordingly, cash and bank balances, investments, bank deposits, deposits with financial institutions, borrowings from banks and financial institutions, other related assets and liabilities and resulting income/expense have been presented as unallocated assets, liabilities, income and expense. Further, all tax assets and liabilities have also been presented as unallocated assets and liabilities.

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 12 November 2026

Deloitte
Haskins & Sells LLP

Chartered Accountants
One International Center,
Tower 3, 31st Floor,
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai - 400 013
Maharashtra, India

Tel: +91 22 6185 6000
Fax: +91 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ALKEM LABORATORIES LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Alkem Laboratories Limited** ("the Company"), which includes a branch located at Nepal, for the quarter and six months ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Rupen K. Bhatt
(Partner)
(Membership No. 046930)
(UDIN: 26046930NUSIDM4802)

Place: Mumbai
Date: November 12, 2026

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Standalone Financial Results for the Quarter and Six months ended 30 September 2026

(₹ in Million except per share data)

	Particulars	Quarter ended			Six months ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	**30.09.2026 (Unaudited)**	30.09.2025 (Unaudited)	31.03.2026 (Audited)
	Continuing Operations						
1	**Income**						
	(a) Revenue from Operations	**30,713.6**	26,677.3	25,420.3	**57,390.9**	49,142.0	96,639.1
	(b) Other Income	**1,218.8**	1,366.2	1,013.7	**2,585.0**	2,179.5	5,551.7
	Total Income	**31,932.4**	28,043.5	26,434.0	**59,975.9**	51,321.5	102,190.8
2	**Expenses**						
	(a) Cost of materials consumed	**7,317.3**	6,728.8	5,676.3	**14,046.1**	11,829.6	24,293.3
	(b) Purchases of stock-in-trade	**1,435.8**	1,466.6	1,228.4	**2,902.4**	2,063.5	4,269.5
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	**(448.7)**	(634.9)	(26.0)	**(1,083.6)**	53.3	(456.7)
	(d) Employee benefits expense	**5,605.4**	5,474.7	4,608.5	**11,080.1**	9,305.9	18,830.3
	(e) Finance costs	**147.1**	175.2	127.5	**322.3**	255.4	572.9
	(f) Depreciation and amortisation expenses	**585.7**	572.2	585.9	**1,157.9**	1,174.8	2,565.6
	(g) Other expenses	**6,888.3**	6,276.7	6,226.3	**13,165.0**	11,978.1	25,458.8
	Total Expenses	**21,530.9**	20,059.3	18,426.9	**41,590.2**	36,660.6	75,533.7
3	**Profit before exceptional items and tax from continuing operations (1) - (2)**	**10,401.5**	7,984.2	8,007.1	**18,385.7**	14,660.9	26,657.1
4	**Exceptional items (Refer note 4)**	**350.0**	-	-	**350.0**	142.9	(1,430.9)
5	**Profit before tax from continuing operations (3) + (4)**	**10,751.5**	7,984.2	8,007.1	**18,735.7**	14,803.8	25,226.2
6	**Tax expense / (credit) (Refer note 5)**						
	(a) Current tax	**3,458.2**	2,077.4	1,235.6	**5,535.7**	2,329.0	4,320.0
	(b) Deferred tax	**(331.5)**	207.0	(465.1)	**(124.5)**	(984.4)	(945.0)
	Total Tax expense (a + b)	**3,126.7**	2,284.4	770.5	**5,411.2**	1,344.6	3,375.0
7	**Profit for the period after tax from continuing operations (5 - 6)**	**7,624.8**	5,699.8	7,236.6	**13,324.5**	13,459.2	21,851.2
	Discontinued operations (Refer note 3)						
	Profit before tax from discontinued operations	-	-	969.5	-	1,490.5	1,490.5
	Tax expense of discontinued operations	-	-	338.8	-	520.8	520.8
8	**Profit from discontinued operations (after tax)**	-	-	630.7	-	969.7	969.7
9	**Profit for the period (7) + (8)**	**7,624.8**	5,699.8	7,867.3	**13,324.5**	14,428.9	22,820.9
10	**Other Comprehensive Income/ (loss) (net of tax)**						
	I. In respect of continuing operations:						
	(a) (i) Items that will not be reclassified to profit or loss	**(34.1)**	(34.2)	(31.3)	**(68.3)**	(62.7)	65.3
	(ii) Income tax relating to items that will not be reclassified to profit or loss	**8.6**	8.6	11.0	**17.2**	22.0	(16.7)
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	II. In respect of discontinued operations:						
	(a) (i) Items that will not be reclassified to profit or loss	-	-	(1.9)	-	(3.6)	(3.6)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	0.6	-	1.2	1.2
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-		-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-		-
	Total Other Comprehensive Income/(loss) (net of tax)	**(25.5)**	(25.6)	(21.6)	**(51.1)**	(43.1)	46.2
11	**Total Comprehensive Income for the period (9) + (10)**	**7,599.3**	5,674.2	7,845.7	**13,273.4**	14,385.8	22,867.1
12	**Paid-up Equity Share Capital** (Face Value ₹ 2 each fully paid up)	**239.1**	239.1	239.1	**239.1**	239.1	239.1
13	**Other Equity**						139,748.5
14	**Earnings Per Share (not annualised for the periods) (for continuing operations) (face value of ₹ 2/- each)**						
	(a) Basic (₹)	**63.77**	47.67	60.53	**111.44**	112.57	182.76
	(b) Diluted (₹)	**63.77**	47.67	60.53	**111.44**	112.57	182.76
	Earnings Per Share (not annualised for the periods) (for discontinued operations) (face value of ₹ 2/- each)						
	(a) Basic (₹)	-	-	5.27	-	8.11	8.11
	(b) Diluted (₹)	-	-	5.27	-	8.11	8.11
	Earnings Per Share (not annualised for the periods) (from total operations) (face value of ₹ 2/- each)						
	(a) Basic (₹)	**63.77**	47.67	65.80	**111.44**	120.68	190.87
	(b) Diluted (₹)	**63.77**	47.67	65.80	**111.44**	120.68	190.87

Statement of Standalone Assets and Liabilities as at 30 September 2026

(₹ in Million)

Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
I. ASSETS		
1 Non-current assets		
(a) Property, plant and equipment	**14,000.1**	14,223.9
(b) Right of use assets	**1,261.0**	870.2
(c) Capital work-in-progress	**1,015.3**	862.7
(d) Other intangible assets	**417.1**	401.0
(e) Intangible assets under development	**349.7**	365.1
(f) Financial Assets		
(i) Investment in subsidiaries and associate	**53,217.5**	41,671.2
(ii) Other investments	**8,817.5**	8,436.6
(iii) Loans	**100.4**	99.2
(iv) Other financial assets	**4,592.9**	10,251.9
(g) Deferred tax assets (net)	**13,979.8**	15,220.9
(h) Current tax assets (net)	**323.9**	327.2
(i) Other non-current assets	**1,594.2**	1,580.2
Total non-current assets	**99,669.4**	94,310.1
2 Current assets		
(a) Inventories	**17,610.6**	16,317.6
(b) Financial Assets		
(i) Investments	**4,659.1**	5,411.5
(ii) Trade receivables	**20,623.3**	15,672.4
(iii) Cash and cash equivalents	**585.9**	654.5
(iv) Bank balances other than (iii) above	**20.6**	12,240.2
(v) Loans	**18.2**	14.2
(vi) Other financial assets	**32,814.9**	21,083.1
(c) Other current assets	**7,093.8**	6,907.7
Total current assets	**83,426.4**	78,301.2
TOTAL ASSETS	**183,095.8**	172,611.3
II. EQUITY AND LIABILITIES		
1 Equity		
(a) Equity share capital	**239.1**	239.1
(b) Other equity	**151,826.3**	139,748.5
Total equity	**152,065.4**	139,987.6
2 Non-current liabilities		
(a) Financial Liabilities		
(i) Lease liabilities	**606.9**	549.5
(ii) Other financial liabilities	**1,361.9**	1,053.5
(b) Provisions	**3,469.1**	3,381.0
(c) Other non-current liabilities	**153.5**	171.6
Total non-current liabilities	**5,591.4**	5,155.6
3 Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	**1,405.4**	5,392.4
(ii) Lease liabilities	**169.5**	172.5
(iii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	**781.8**	792.1
Total outstanding dues of creditors other than micro and small enterprises	**13,951.0**	13,969.2
(iv) Other financial liabilities	**4,661.3**	3,996.4
(b) Other current liabilities	**910.4**	1,061.9
(c) Provisions	**1,847.2**	1,674.1
(d) Current tax liabilities (net)	**1,712.4**	409.5
Total current liabilities	**25,439.0**	27,468.1
Total liabilities	**31,030.4**	32,623.7
TOTAL EQUITY AND LIABILITIES	**183,095.8**	172,611.3

Statement of Standalone Cash Flow for the six months ended 30 September 2026

(₹ in Million)

	Particulars	For the six months ended 30 September 2026 (Unaudited)	For the six months ended 30 September 2025 (Unaudited)
A.	**Cash Flow from Operating Activities:**		
	Profit before tax and after exceptional items		
	Continuing operations	18,735.7	14,803.8
	Discontinued operations	-	1,490.5
	Adjustments for:		
	Depreciation and amortisation expense	1,157.9	1,217.2
	Unrealised loss on fair valuation of investments (net) through FVTPL	16.2	294.7
	Profit on sale of investments (net)	(167.2)	(234.1)
	Gain on sale / write off of property plant and equipment (net)	0.8	(141.8)
	Dividend income from subsidiaries	(56.4)	(40.8)
	Provision for doubtful advances	-	(4.8)
	Interest income	(1,784.4)	(1,629.7)
	Interest expenses	322.3	268.7
	Expected credit loss on receivables	(47.6)	205.0
	Rental income	(29.4)	(15.8)
	Unrealised foreign currency (gain)/ loss on revaluation (net)	51.1	(27.3)
	Subtotal of adjustments	(536.7)	(108.7)
	Operating profit before working capital changes	18,199.0	16,185.6
	Adjustments for changes in working capital:		
	(Increase) in trade receivables	(5,078.5)	(1,860.0)
	Decrease/ (Increase) in loans, other financial assets and other assets	15.9	(1,226.5)
	(Increase)/ decrease in inventories	(1,293.0)	60.1
	Increase / (Decrease) in trade payable, other financial liabilities and other liabilities	603.3	(216.4)
	Increase in provisions	58.6	40.8
	Subtotal of adjustments for changes in working capital	(5,693.7)	(3,202.0)
	Cash generated from operations	12,505.3	12,983.6
	Less: Income taxes paid (net of refund)	(2,863.8)	(1,906.7)
	Net cash generated from operating activities	9,641.5	11,076.9
B	**Cash Flow from Investing Activities:**		
	Purchases of property, plant and equipment (including capital work in progress, other intangible assets and intangible assets under development net off capital advances and capital creditors)	(978.0)	(1,381.0)
	Proceeds from disposal of property, plant and equipment	19.4	1,080.4
	Investments in subsidiaries and associate	(11,546.3)	(8,200.0)
	Investments made in fixed deposits	(6,369.8)	(16,376.7)
	Redemption of fixed deposits	12,642.4	10,845.7
	Other investments made	(14,785.3)	(9,893.3)
	Redemption of other investments	15,209.3	8,305.3
	Recovery from impaired investment	51.0	-
	Dividend received	56.4	40.8
	Interest received	1,451.9	1,341.5
	Rent received	29.4	15.8
	Net cash generared used in investing activities	(4,219.6)	(14,221.5)
C	**Cash Flow from Financing Activities:**		
	Proceeds from /(repayment) of current borrowings (net)	(3,190.5)	4,416.6
	Principal repayment of lease liabilities	(136.8)	(149.0)
	Dividend paid	(1,195.7)	(956.5)
	Interest paid	(170.8)	(155.0)
	Net cash (used in) / generated from financing activities	(4,693.8)	3,156.1
D	**Net (decrease)/ increase in cash and cash equivalents (A+B+C)**	728.1	11.5
E	**Cash and cash equivalents as at beginning of the period (net of loans repayable on demand from banks)**	(1,529.1)	120.4
F	**Cash and cash equivalents as at end of the period (net of loans repayable on demand from banks) (D+E)**	(801.0)	131.9

Notes:

1 **Components of cash and cash equivalents for the purpose of Cash flow as per IND AS 7:**

Cash and cash equivalents	585.9	485.0
Loans repayable on demand from banks	(1,386.9)	(353.1)
Total cash and cash equivalents as at end of the period (net of loans repayable on demand from banks)	**(801.0)**	**131.9**

2 The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - "Statement of Cash Flows"

Notes to the Standalone Financial results:

1 The above standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2 The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 11 November 2026 and subsequently approved by the Board of Directors at its meeting held on 12 November 2026. The auditors have issued an unmodified review report on the financial results for the quarter and six months ended 30 September 2026.

3 The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. The Company had executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its Generic business to Alkem Wellness Limited.

During the earlier periods, the transfer of the Generic Business had been disclosed as discontinued operations in accordance with Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". The figures for the previous periods have been restated to give effect to the presentation requirement of Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations".

Key financial information of Discontinued Operations:

(₹ in Million)

Particulars	Quarter ended			Six months ended		Year ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
Total income	-	-	5,622.8	-	9,181.0	9,181.0
Total expenses	-	-	4,653.3	-	7,690.5	7,690.5
Profit before tax	-	-	969.5	-	1,490.5	1,490.5
Total tax expense	-	-	338.8	-	520.8	520.8
Net profit for the period after tax	-	-	630.7	-	969.7	969.7

4 Exceptional items include:

a) Exceptional item for the quarter and six months ended 30 September 2026 represents recovery of ₹ 350 million against investment made, which was impaired during the quarter and year ended 31 March 2026.

b) Exceptional item amounting to ₹142.9 million for the six months ended 30 September 2025 is on account of gain on sale of Indore facility which was impaired earlier.

c) Exceptional items amounting to ₹1,430.9 million for the year ended 31 March 2026 is on account of
- Impact of labour code of ₹ 826.8 million towards gratuity and leave encashment for past service cost.
- Impairment of real estate investment made of ₹747 million.
- Gain on sale of Indore facility of ₹142.9 million.

5 During the year ended 31 March 2026, pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Company had decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax had been recognised at the substantially enacted rate as at 31 March 2026. Subsequently in the current period, the tax expense has been recognized based on the enacted tax rates applicable under the new regime.

6 The Company operates in one reportable business segment i.e. "Pharmaceuticals".

By Order of the Board
For Alkem Laboratories Limited

B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 12 November 2026